Development of a novel nitric oxide (NO) production inhibitor with potential therapeutic effect on chronic inflammation
作者:Youzhe Yang、Zhe Wei、Alexander Tobias Teichmann、Frank Heinrich Wieland、Amu Wang、Xiangui Lei、Yue Zhu、Jinxiang Yin、Tiantian Fan、Li Zhou、Chao Wang、Lijuan Chen
DOI:10.1016/j.ejmech.2020.112216
日期:2020.5
at 10 μM (IC50 = 6.4 μM) with the lowest cytotoxicity (IC50 > 80 μM) among the tested compounds. Besides, western blot analysis indicated that compound 53 was a potent down-regulator of inducible nitric oxide synthase (iNOS) protein. Docking study revealed that compound 53 also can dock into the active site of iNOS. Furthermore, at the dose of 10 mg/kg/day, compound 53 could both significantly suppress
炎症是对刺激的复杂生物学反应。活化的巨噬细胞诱导过度释放促炎性细胞因子,而内源性自由基一氧化氮(NO)等介体在多种炎性疾病的进展中起重要作用。天然和合成查耳酮都具有广泛的生物活性。在这项工作中,基于生物活性卡瓦尔查耳酮,设计,合成了39个查耳酮和3种相关化合物,包括几种新化合物,并评估了它们对RAW 264.7细胞中NO产生的抑制作用。新型化合物(E)-1-(2'-羟基-4',6'-二甲氧基苯基)-3-(3-甲氧基-4-(3-吗啉代丙氧基)苯基)丙-2-烯-1-酮(53)对10μM(IC的NO产生)表现出更好的抑制活性(84.0%)50 = 6.4μM)的细胞毒性(IC 50 > 80μM)在测试化合物中最低。此外,蛋白质印迹分析表明化合物53是诱导型一氧化氮合酶(iNOS)蛋白的有效下调剂。对接研究表明,化合物53也可以对接iNOS的活性位点。此外,在剂量为10 mg / kg /